What changed for Cystic Fibrosis
A plain English summary of what recently moved in the public data Voxsanity tracks for Cystic Fibrosis. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 129 to 132 (+3)
- Trials on record 1,445 to 1,446 (+1)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Cystic Fibrosis in July 2026. Voxsanity tracks 8 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 155 trials tracked for Cystic Fibrosis that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT05453578 · results posted 16 July 2026
According to the results reported on ClinicalTrials.gov, this trial tested an intravenous bacteriophage treatment (a therapy using viruses that target bacteria) against a placebo in people with *Pseudomonas aeruginosa* lung infections, likely in the context of cystic fibrosis or a similar condition. The trial ran in two stages: a small early safety-focused stage (Stage 1) with 6 participants across three dose levels, and a larger Stage 2 involving 67 participants spread across three dose groups and a placebo group. In total, 73 people started the study and 71 completed it. The reported data s...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05616221 · results posted 5 January 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05616221) tested an inhaled investigational treatment called AP-PA02 — a type of bacteriophage (a virus designed to target bacteria) — in people with a bacterial lung infection caused by *Pseudomonas aeruginosa*. A total of 48 people started the trial, divided into two cohorts (groups) and given either one of two doses of AP-PA02 or a placebo (an inactive treatment). The trial was measuring changes in the amount of *Pseudomonas aeruginosa* bacteria found in sputum (mucus coughed up from the lungs) one week after the treatm...
-
NCT04375514 · results posted 17 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04375514) tested an inhaled investigational drug called ARO-ENaC across two groups of participants: healthy volunteers and people with cystic fibrosis. A total of 43 people took part — 36 healthy volunteers and 7 people with cystic fibrosis. Participants received different doses of ARO-ENaC (ranging from 20 mg to 180 mg, given over several days) or a placebo (an inactive treatment used for comparison). The trial was primarily measuring how many participants experienced adverse events — that is, any unwanted medical occurre...
-
NCT04594369 · results posted 16 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04594369) looked at a medicine called brensocatib in people with a lung condition called bronchiectasis. A total of 1,721 people took part — 583 received a 10 mg daily dose of brensocatib, 575 received a 25 mg daily dose, and 563 received a placebo (a dummy treatment with no active ingredient). The main thing the trial was measuring was how often participants had "pulmonary exacerbations" — that is, flare-ups of lung symptoms serious enough for a doctor to prescribe antibiotics — over the course of a year. The reported da...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05865886 · results posted 18 November 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 22 people in total — 7 received a placebo (a dummy treatment with no active ingredient) and 15 received a 5 mg dose of the investigational medicine BI 1291583. All 7 placebo participants and 14 of the 15 in the active medicine group completed the study (one person in the active group did not finish). The trial was primarily measuring how often participants experienced adverse events — that is, any unwanted or unexpected health changes that occurred during the study period — and also looked at how the medicine moved th...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03506061 · results posted 11 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03506061) enrolled 42 people with cystic fibrosis across two groups: 22 people who showed signs of partial lung function (based on sweat chloride levels or pancreatic status), and 20 people who carry a specific genetic variation called N1303K. Of the 42 who started, 40 completed the study. The trial was measuring several things, including how much air participants could forcefully breathe out in one second (called FEV1, expressed as a percentage of what would be expected for a healthy person of the same age and size), the...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05006573 · results posted 20 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05006573) enrolled 99 people with a lung condition called non-cystic fibrosis bronchiectasis — 54 received the study drug benralizumab (30 mg) and 45 received a placebo (a dummy treatment). The trial was split into two phases: a double-blind period (where neither participants nor doctors knew who received which treatment) and an open-label extension period (where everyone knew). The main thing the trial was measuring was how often participants had flare-ups (called exacerbations) of their bronchiectasis over the course of...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT04183790 · results posted 18 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04183790) involved 64 participants in the main group receiving a triple combination medicine called ELX/TEZ/IVA, plus 2 additional participants included for a specific analysis. The trial was designed for people with cystic fibrosis, and it measured safety-related events as its main focus, alongside several secondary measurements including lung function, a sweat test, quality of life, and body weight indicators. The reported data shows that, for the primary focus on safety-related events, 64 participants were recorded as...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02496780 · results posted 17 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02496780) enrolled 65 people across four groups: 12 received a placebo, 13 received a long-acting insulin called Levemir, 15 received a fast-acting insulin called Novolog, and 25 were healthy volunteers included for comparison. The trial was measuring how the body breaks down its own proteins — a process sometimes called "protein turnover" — in people with cystic fibrosis (CF), and whether four weeks of insulin treatment changed that rate compared to a placebo. Not everyone who started the trial finished it: by the end, 11...
-
NCT04938726 · results posted 13 February 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04938726) involved 15 people in total — 10 in the Ketone Monoester group and 5 in the Placebo group. Of those, 9 from the Ketone Monoester group and all 5 from the Placebo group completed the trial. The trial was measuring lung function, a marker of inflammation in the body, and how participants felt about their own breathing and respiratory health. The reported data shows the following numbers for the two groups. For lung function (measured as the amount of air a person can forcefully breathe out in one second, called FE...
-
NCT02038803 · results posted 6 December 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 5 adults with cystic fibrosis. The study was looking at whether participants would stick to (adhere to) their antibiotic treatment — specifically comparing an inhaled solution called Tobramycin with a dry-powder inhaler version called TOBI Podhaler. Each person acted as their own comparison point, meaning their experience with one treatment was compared to their experience with the other. It is worth noting that none of the 5 participants who started the study were recorded as having completed it. The reported data s...
-
NCT06350474 · results posted 26 November 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 477 people with cystic fibrosis — 240 in a group that stopped taking a medication called DNase (also known as dornase alfa), and 237 in a group that continued taking it. The trial was designed to find out whether stopping DNase while on a newer cystic fibrosis treatment was "non-inferior" — meaning not meaningfully worse — compared to continuing it. The main thing being measured was a breathing test result called FEV1 % predicted, which is a standard way of measuring how much air a person can forcefully breathe out, e...
-
NCT03277196 · results posted 23 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03277196) enrolled 86 people who were given ivacaftor, a medicine used in the treatment of cystic fibrosis. Of those 86 participants, 38 had previously been on ivacaftor (described as "rollover participants") and 48 had never taken it before ("ivacaftor-naïve"). The trial was primarily looking at the safety and tolerability of the medicine — in other words, tracking any unwanted or unexpected health events that occurred while participants were taking it. A secondary measurement looked at changes in sweat chloride levels, a...
-
NCT03265288 · results posted 9 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03265288) enrolled 83 people in the LAU-7b group and 83 people in the placebo group — 166 participants in total. The trial was studying a treatment called LAU-7b in people with cystic fibrosis. The main things being measured were changes in lung function (using a breathing test called FEV1, which measures how much air a person can forcefully breathe out in one second, expressed as a percentage of what would be expected for someone of their age and size) and the occurrence of side effects during the study. The trial ran for...
-
NCT06350461 · results posted 1 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT06350461) enrolled 370 people with cystic fibrosis — 184 in a group that stopped using hypertonic saline (a saltwater inhaled therapy, labelled "HS-Discontinue") and 186 in a group that kept using it ("HS-Continue"). The vast majority finished the study: 181 and 183 participants respectively. The trial was primarily measuring whether stopping hypertonic saline made a difference to lung function — specifically a breathing test called FEV1 (how much air a person can forcefully breathe out in one second, expressed as a percen...
-
NCT04853368 · results posted 16 July 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04853368) enrolled 48 people with cystic fibrosis across three groups (called cohorts). The trial tested different three-drug combinations — involving investigational medicines called galicaftor, navocaftor, ABBV-119, and ABBV-576 — in people with specific genetic types of cystic fibrosis. The study ran in two phases: a lead-in period of about a month where participants took a two-drug combination, followed by a second month where they were assigned to a triple-drug combination or, in one group, a placebo (a dummy treatmen...
-
NCT02694393 · results posted 24 June 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02694393) involved just two participants who inhaled a treatment called nebulized nitrite — meaning a nitrite solution delivered as a fine mist to breathe in. One participant completed the trial and one did not. The trial was measuring lung function and certain markers in breath and mucus (sputum) after the inhalation. The reported data shows that the main (primary) measure was lung function, specifically a breathing test called FEV1 — short for "forced expiratory volume in one second," which is a measure of how much air...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05076149 · results posted 13 June 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 289 people in the ELX/TEZ/IVA group and 284 people in the VX-121/TEZ/D-IVA group at the start. The trial was comparing two combination medicines being studied for cystic fibrosis. The main thing the trial measured was a lung function test called FEV1 — specifically the amount of air a person can forcefully breathe out in one second — expressed as a percentage of what would be expected for someone of their age, height, and sex. It also measured sweat chloride levels, which is the amount of salt in sweat (a marker often...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05033080 · results posted 10 June 2024
According to the results reported on ClinicalTrials.gov, this trial compared two combination drug regimens in people with cystic fibrosis: one called ELX/TEZ/IVA and another called VX-121/TEZ/D-IVA. Around 202 people were assigned to the first group and 196 to the second group, with the vast majority completing the trial (191 and 184 respectively). The trial's main focus was on measuring lung function — specifically a breathing test called FEV1, which measures how much air a person can forcefully breathe out in one second — and also on sweat chloride levels, a marker commonly used in cystic fi...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04545515 · results posted 8 May 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04545515) enrolled 120 participants, all of whom received a combination treatment referred to as ELX/TEZ/IVA. The trial was set up in two back-to-back phases: one group of 61 participants had previously received a placebo before switching to ELX/TEZ/IVA, while another group of 59 had already been on ELX/TEZ/IVA and continued with it. In total, 110 participants completed the study and 10 did not. The trial was measuring safety and tolerability (whether unwanted health events occurred), as well as changes in two body measure...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03525574 · results posted 8 May 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03525574) enrolled 507 participants in the main treatment group (ELX/TEZ/IVA — a triple combination of three medicines: elexacaftor, tezacaftor, and ivacaftor) plus 3 additional participants included for a specific analysis, giving a total of 510 people at the start. The trial was an open-label extension study, meaning all participants received the triple combination medicine. It was measuring safety-related events, lung function, a sweat test marker, and the number of lung flare-ups (called pulmonary exacerbations) over t...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03551691 · results posted 30 April 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 19 participants in total — 9 in the group that received the study drug (omeprazole) first and then a placebo, and 10 in the group that received the placebo first and then the study drug. Thirteen participants completed the trial (6 and 7 from each group respectively), while 6 did not complete it. The trial was measuring how well the body absorbs fat, and whether omeprazole — a medicine that reduces stomach acid — had any effect on that process in participants who have difficulty absorbing fat. The reported data shows...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01180634 · results posted 30 April 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 330 people with cystic fibrosis — 220 received an inhaled antibiotic called Aeroquin (levofloxacin) at a dose of 240 mg, and 110 received a placebo (a dummy treatment with no active ingredient). Of those who started, 210 in the Aeroquin group and 109 in the placebo group completed the study. The trial was mainly measuring how long it took for participants to experience a lung flare-up (called an exacerbation — a worsening of respiratory symptoms meeting a set of defined criteria). It also measured changes in lung func...
-
NCT04596319 · results posted 31 January 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 29 participants across seven groups. The groups were split into "SAD" (single ascending dose — meaning participants received one dose, with different groups receiving increasing amounts) and "MAD" (multiple ascending dose — meaning participants received several doses over time). Some participants in each type received a placebo (an inactive treatment used for comparison). The trial was measuring how often and how severely participants experienced side effects, known as "treatment-emergent adverse events" — that is, an...
-
NCT04058366 · results posted 16 January 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04058366) enrolled 251 participants who were taking a combination medicine called ELX/TEZ/IVA (elexacaftor/tezacaftor/ivacaftor), a treatment for cystic fibrosis. Of those, 215 completed the study and 36 did not. The trial was measuring safety-related events as its main goal, along with several secondary measures including lung function, sweat chloride levels (a marker used in cystic fibrosis monitoring), and body weight and BMI (a measure of body size based on height and weight). The reported data shows that, for the pri...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03460704 · results posted 29 December 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03460704) enrolled 152 people in the Colistimethate Sodium (CMS) group and 135 people in the placebo group, for a total of 287 participants. The trial was measuring how often people with a lung condition called non-cystic fibrosis bronchiectasis experienced "pulmonary exacerbations" — that is, episodes where their symptoms (such as increased cough, more mucus, breathlessness, or fever) worsened significantly and a doctor prescribed antibiotic tablets or injections to treat them. The study tracked how many of these episodes...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT03093974 · results posted 15 November 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03093974) looked at a inhaled medication called Colistimethate Sodium (CMS) compared to an inactive placebo, in people with a lung condition called non-cystic fibrosis bronchiectasis (a condition where the airways are permanently widened and prone to infection). A total of 177 people started in the CMS group and 200 in the placebo group, with 176 and 197 respectively included in the main analysis. The primary thing the trial measured was how often participants had a "pulmonary exacerbation" — that is, a flare-up of lung s...
-
NCT03104855 · results posted 12 October 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 10 people in total — 5 with cystic fibrosis (CF) and 5 healthy volunteers without CF. All 10 participants completed the study, with no dropouts. The trial was measuring how the body processes a specially labelled form of vitamin D (called D6-25(OH)D3, a tracking version of vitamin D used to follow its journey through the body). Researchers looked at how quickly the body cleared it from the blood, how long it stayed in the body, and how it was broken down — comparing the CF group to the healthy group. The reported dat...
-
NCT04969224 · results posted 3 October 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 82 adults who received a combination treatment called ELX/TEZ/IVA (elexacaftor/tezacaftor/ivacaftor). Of those 82 participants, 80 completed the study and 2 did not. The trial was measuring two main things: how much participants' coughing frequency changed over the course of the study, and whether their daily step count (as a measure of physical activity) changed. The reported data shows that, on average, participants' cough frequency — measured as the number of cough events recorded each day — was reported to have r...
-
NCT03924947 · results posted 28 September 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03924947) ran in two separate parts and involved a total of 50 participants across both parts (26 in Part 1 and 24 in Part 2). The trial was measuring how well the digestive system absorbed fat and protein — specifically in people taking a pancreatic enzyme replacement called Creon, compared to modified versions of it (referred to as "Creon MP" in Part 1 and "Creon AAPIS" in Part 2). The main thing being measured was the "Coefficient of Fat Absorption" (CFA) — simply put, the percentage of fat from food that the body actua...
See all 155 reported results for Cystic Fibrosis
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, public investment in Cystic Fibrosis research is substantial and has been growing year on year. This rising trend is an encouraging signal, suggesting that the scientific and medical community continues to see real value in pursuing new answers for people living with this condition. For patients, a sustained and increasing level of government research funding general...
See the full Cystic Fibrosis page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.